Amy Schulman, named to head one of Pfizer’s three new drug units starting next month, will instead leave the company.
Schulman, a deputy to Chief Executive Officer Ian Read and Pfizer’s general counsel, was chosen in July to lead one of the businesses as the New York-based company reorganizes ahead of a potential breakup. Albert Bourla, a 20-year Pfizer veteran, will now head the unit, which handles vaccines, oncology and consumer health products, Pfizer said in a statement today. The company didn’t give a further reason for Schulman's departure or say she was leaving for another job. Read the full story.